ClinicalTrials.gg
TerminatedNCT01215136Updated Nov 24, 2023Results posted

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

A Phase 2 interventional study of Everolimus and Everolimus in Transitional Cell Carcinoma, Bladder Carcinoma and Urothelial Carcinoma, sponsored by Matthew Galsky. Terminated at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-24.

Sponsored by Matthew Galsky · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Lack of Accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies testing paclitaxel in Carcinoma, Transitional Cell — none open to participants now, 1 under way, none of them phase 3. Paclitaxel · Carcinoma, Transitional Cell.

Enrollment
9th of 12
36 · median 44
Started
2010
the only one that year
Phase 2
11 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
1 of 12
Matthew Galsky

Among the 12 studies testing paclitaxel in Carcinoma, Transitional Cell, this one is the 9th largest by enrollment, is the only one that started in 2010, is one of 11 in phase 2, and was the 4th registered.

Carcinoma, Transitional Cell

633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

None of the 12 studies testing paclitaxel in Carcinoma, Transitional Cell is open now. The open studies under Carcinoma, Transitional Cell, anywhere →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 149 Carcinoma, Transitional Cell studies recruiting now, 123 (83%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing paclitaxel in Carcinoma, Transitional Cell as a file.
02

Study summary

The purpose of this trial is to explore the activity and safety of everolimus +/- paclitaxel as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma.

Read the detailed description

OUTLINE: This is a multi-center study

Patients will be enrolled into one of two parallel cohorts:

  • Cohort 1: impaired renal function AND poor performance status (cycle length = 28 days). Everolimus 10 mg orally daily
  • Cohort 2: impaired renal function OR poor performance status (cycle length = 28 days). Everolimus 10 mg orally daily + IV Paclitaxel 80 mg/m2 on D1, 8, 15

Restaging evaluations will be performed after every 2 cycles.

Treatment will continue until disease progression or unacceptable toxicity.

Karnofsky performance status 60-70%

Life Expectancy: Not specified

Hematopoietic:

  • Absolute neutrophil count (ANC) ≥ 1.5 K/mm3
  • Hemoglobin (Hgb) ≥ 9 g/dL
  • Platelets ≥ 100 K/mm3
  • INR ≤ 1.5 (Anticoagulants are allowed if target INR ≤ 1.5 on a stable dose of warfarin or on a stable dose of Low molecular weight (LMW) heparin for at least 2 weeks prior to registration for protocol therapy).
  • Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L
  • Fasting triglycerides ≤ 2.5 x ULN.
  • Fasting serum glucose \< 1.5 x ULN

Hepatic:

  • Bilirubin ≤ 1.5 x ULN
  • Aminotransferases (AST and ALT) ≤ 2.5 x ULN (unless liver metastases, then ≤ 5 x ULN)

Renal:

  • Calculated creatinine clearance of \< 60 using the Cockcroft-Gault formula

Cardiovascular:

  • No symptomatic congestive heart failure of New York heart Association Class III or IV.
  • No unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.
03

Conditions studied

  • Transitional Cell Carcinoma
  • Bladder Carcinoma
  • Urothelial Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological proof of transitional cell carcinoma (TCC) of the bladder, urethra, ureter, or renal pelvis (urothelial carcinoma). Histology may be mixed, but still requires a component of TCC.
  • according to and obtained by imaging within 30 days prior to registration for protocol therapy.
  • Must be ineligible for cisplatin, based on the following, within 30 days prior to registration for protocol therapy.
  • Prior radiation therapy is allowed to \< 25% of the bone marrow.
  • Written and HIPAA authorization for release of personal health information.
  • Age > 18 years at the time of consent.
  • Females of and males must be willing to use an effective method of (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 8 weeks after treatment discontinuation.
  • Females of childbearing potential must have a negative pregnancy test within 7 days prior to prior to registration for protocol therapy.
  • Females must not be breastfeeding.

Exclusion criteria

Exclusion Criteria:

  • No prior chemotherapy for disease. Prior chemotherapy in the /adjuvant setting is allowed if completed at least 12 months prior to registration for protocol therapy.
  • No active or . Patients with neurological symptoms must undergo a head CT scan or brain MRI to exclude brain metastasis.
  • No prior is allowed except for adequately treated basal cell or adequately treated squamous cell skin cancer, in situ cervical cancer, Gleason ≤ grade 7 prostate cancers (treated definitively with no evidence of PSA progression), or other cancer for which the patient has been disease-free for at least 5 years.
  • No treatment with any anticancer therapy or agent within 30 days prior to registration for protocol therapy.
  • No known to any protocol treatment.
  • No prior treatment with mTOR inhibitor (sirolimus, temsirolimus, everolimus).
  • No history of immunization with attenuated within one week prior to registration for protocol therapy or during study period.
  • No severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air.
  • No uncontrolled diabetes as defined by fasting serum glucose >1.5 x .
  • No active (acute or chronic) or uncontrolled severe infections.
  • No liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.
  • No known history of seropositivity.
  • No impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).
  • No active, bleeding diathesis.
  • No history of major surgery (defined as requiring general anesthesia) or significant traumatic injury within 30 days prior to registration for protocol therapy.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    Cohort 1

    Single-agent everolimus (enrollment limited to patients with patients with creatinine clearance \< 60 ml/min AND Karnofsky performance status of 60-70%)

    Drug: Everolimus

  • Active comparator
    Cohort 2

    Everolimus plus paclitaxel (enrollment limited to patients with creatinine clearance \< 60 ml/min OR Karnofsky performance status of 60-70%)

    Drug: Everolimus · Drug: Paclitaxel

Interventions

  • 10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.

  • 10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.

  • Paclitaxel 80 mg/m2 IV as a 1 hour infusion on days 1, 8, and 15, of a 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Response Rate of Single-Agent Everolimus and Everolimus + Paclitaxel

    To evaluate clinical benefit rate (complete response, partial response, and stable disease) at 4 months from initiation of treatment.

    Time frame: 4 months

Secondary outcomes

  1. Number of Adverse Events as a Measure of Safety and Tolerability

    To determine the safety of everolimus and everolimus plus paclitaxel in this patient population. A summary with the count of events per grade is provided.

    Time frame: 5 months

  2. Progression Free Survival

    To determine median progression free survival per RECIST 1.1, per cohort.

    Time frame: 4 months

  3. Overall Survival

    To determine median overall survival at 1-year from the initiation of treatment.

    Time frame: 12 months

07

Results

Posted Nov 24, 2023

Participant flow

Participant flow — Overall Study
MilestoneEverolimusEverolimus Plus Paclitaxel
Started729
Completed12
Not completed627
Withdrew: Adverse event29
Withdrew: Disease progression314
Withdrew: Symptomatic deterioration11
Withdrew: Death02
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryResponse Rate of Single-Agent Everolimus and Everolimus + Paclitaxel

To evaluate clinical benefit rate (complete response, partial response, and stable disease) at 4 months from initiation of treatment.

Time frame:
4 months
Reported as:
Number · percentage of participants
Response Rate of Single-Agent Everolimus and Everolimus + Paclitaxel
percentage of participantsCohort 1Cohort 2
Response Rate of Single-Agent Everolimus and Everolimus + Paclitaxel14.337.9
SecondaryNumber of Adverse Events as a Measure of Safety and Tolerability

To determine the safety of everolimus and everolimus plus paclitaxel in this patient population. A summary with the count of events per grade is provided.

Time frame:
5 months
Reported as:
Number · Number of Events
Number of Adverse Events as a Measure of Safety and Tolerability
Number of EventsCohort 1Cohort 2
Grade 1 Adverse Events10116
Grade 2 Adverse Events975
Grade 3 Adverse Events439
Grade 4 Adverse Events01
Grade 5 Adverse Events03
SecondaryProgression Free Survival

To determine median progression free survival per RECIST 1.1, per cohort.

Time frame:
4 months
Reported as:
Median · months
Progression Free Survival
monthsCohort 1Cohort 2
Progression Free Survival2.3327 (1.6099 to 3.5483)5.8480 (2.9569 to 7.6550)
SecondaryOverall Survival

To determine median overall survival at 1-year from the initiation of treatment.

Time frame:
12 months
Reported as:
Median · months
Overall Survival
monthsCohort 1Cohort 2
Overall Survival4.5010 (2.2341 to 8.3121)10.8747 (6.8337 to 14.3573)

Adverse events

Collected over All-Cause Mortality was monitored up to a maximum of 12 months. Serious Adverse Events and Other (Not Including Serious) Adverse Events were monitored for up to 5 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 17/7 (100%)1/7 (14.3%)5/7 (71.4%)
Cohort 225/29 (86.2%)11/29 (37.9%)28/29 (96.6%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventCohort 1Cohort 2
INFECTIONS AND INFESTATIONS - OTHER, SPECIFYInfections and infestations1/72/29
PNEUMONITISRespiratory, thoracic and mediastinal disorders0/72/29
URINARY TRACT INFECTIONInfections and infestations0/72/29
DEHYDRATIONMetabolism and nutrition disorders0/71/29
DIARRHEAGastrointestinal disorders0/71/29
DYSPNEARespiratory, thoracic and mediastinal disorders0/71/29
EDEMA LIMBSGeneral disorders0/71/29
GENERALIZED MUSCLE WEAKNESSMusculoskeletal and connective tissue disorders0/71/29
HEPATOBILIARY DISORDERS - OTHER, SPECIFYHepatobiliary disorders0/71/29
LUNG INFECTIONInfections and infestations0/71/29
Most frequent other events
Showing 10 of 63
Most frequent other events
EventCohort 1Cohort 2
ANEMIABlood and lymphatic system disorders2/717/29
FATIGUEGeneral disorders3/715/29
MUCOSITIS ORALGastrointestinal disorders2/714/29
ALOPECIASkin and subcutaneous tissue disorders0/713/29
DIARRHEAGastrointestinal disorders2/711/29
PERIPHERAL SENSORY NEUROPATHYNervous system disorders0/711/29
NAUSEAGastrointestinal disorders1/710/29
NEUTROPHIL COUNT DECREASEDInvestigations0/79/29
HYPERTRIGLYCERIDEMIAMetabolism and nutrition disorders0/77/29
ANOREXIAMetabolism and nutrition disorders1/76/29

Baseline characteristics

Age, Continuous
Age, Continuous(years)EverolimusEverolimus Plus PaclitaxelTotal
Mean78 (59 to 90)72.14 (54 to 88)73.28 (54 to 90)
Sex: Female, Male
Sex: Female, Male(Participants)EverolimusEverolimus Plus PaclitaxelTotal
Female279
Male52227
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EverolimusEverolimus Plus PaclitaxelTotal
Hispanic or Latino011
Not Hispanic or Latino72835
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EverolimusEverolimus Plus PaclitaxelTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American224
White52732
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)EverolimusEverolimus Plus PaclitaxelTotal
United States72936
Karnovsky Performance Status (KPS) at Screening
Karnovsky Performance Status (KPS) at Screening(Participants)EverolimusEverolimus Plus PaclitaxelTotal
KPS 100044
KPS 90066
KPS 8001212
KPS 70145
KPS 60639
08

Study locations

11 sites
  • University of Alabama Hematology Oncology Clinic at Medical West
    Birmingham, Alabama 35294, United States
  • Northwestern University, Robert H. Lurie Comprehensive Cancer Center
    Chicago, Illinois 60611, United States
  • Cancer Care Center of Southern Indiana
    Bloomington, Indiana 47403, United States
  • Indiana University Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • IU Health Central Indiana Cancer Centers
    Indianapolis, Indiana 46219, United States
  • Metro Health Cancer Care
    Wyoming, Michigan 49519, United States
  • Nebraska Cancer Specialists
    Omaha, Nebraska 68114, United States
  • Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center
    New York, New York 10029, United States
  • MUSC Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • University of Texas Medical Branch
    Galveston, Texas 77555, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
09

References and documents

Publications

  • Jun T, Hahn NM, Sonpavde G, Albany C, MacVicar GR, Hauke R, Fleming M, Gourdin T, Jana B, Oh WK, Taik P, Wang H, Varadarajan AR, Uzilov A, Galsky MD. Phase II Clinical and Translational Study of Everolimus +/- Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma. Oncologist. 2022 Jun 8;27(6):432-e452. doi: 10.1093/oncolo/oyab075. PubMed 35438782 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Apr 2017 and a completion of Apr 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2023, 6 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2010
First posted
Oct 6, 2010
Start
Dec 2010
Primary completionActual
Apr 24, 2017
CompletionActual
Apr 24, 2018
Results first posted
Nov 24, 2023
Last update
Nov 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01215136
Lead sponsor
Matthew Galsky
Collaborators
Hoosier Cancer Research Network, Novartis Pharmaceuticals
Responsible party
Matthew Galsky (Sponsor-Investigator, Hoosier Cancer Research Network) — Sponsor-investigator
First posted
Oct 6, 2010
Start date
Dec 2010
Primary completion
Apr 24, 2017
Completion
Apr 24, 2018
Results posted
Nov 24, 2023
Last update
Nov 24, 2023

Study contacts

Matthew Galsky, M.D.
study chair · Hoosier Cancer Research Network

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion